Vanguard's reduction below 5% removes a large passive holder from reporting obligations, potentially reducing buying support. Monitor for further insider or institutional selling pressure, especially given the clinical-stage nature of Xencor's pipeline and the upcoming End of Phase 1 FDA meeting in 1H2027.
Price Chart
Executive Summary
Vanguard Capital Management filed an amended Schedule 13G for Xencor Inc, disclosing a reduced passive stake of 3,710,894 shares (4.99%) as of September 30, 2026, down from 10,816,417 shares (14.5%) reported by BlackRock three days earlier. The decrease below the 5% threshold signals a significant reduction in Vanguard's position, though the filing remains a routine passive update by a large asset manager.
Key Financial Metrics
Key Facts
- Vanguard Capital Management disclosed beneficial ownership of 3,710,894 shares of Xencor common stock as of September 30, 2026.
- The stake represents 4.99% of outstanding shares, down from a prior level above 5%.
- The filing is a passive investment disclosure under Rule 13d-1(b); no activist intent is indicated.
- Vanguard's stake decreased by approximately 65% compared to the 10,816,417 shares (14.5%) reported by BlackRock in a separate 13G/A filed three days earlier.
- The filing was made by Vanguard Capital Management LLC, including shares held by affiliated entities and Vanguard funds.
Financial Impact
Vanguard reduced its stake by approximately 7.1 million shares, valued at roughly $157 million based on the $2.2B market cap and 4.99% stake. The reduction represents about 9.5% of shares outstanding.
Risk Factors
- Large passive holder reduced stake by ~65%, signaling reduced institutional confidence.
- Stake now below 5% threshold, eliminating Vanguard's obligation to report future changes.
- Clinical-stage biotech with no approved products; reliance on regulatory milestones for value inflection.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G/A Filing (Primary) | 0002100119-26-001691 |
| Document: 0002100119-26-001691-index.html | 0002100119-26-001691 |
| Document: 0002100119-26-001691.txt | 0002100119-26-001691 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 30, 2026 1d ago | SC 13G/A | $29.09 | awaiting T+1 | awaiting T+1 | $29.82 (−2.51%) |
Oct 27, 2026 4d ago | SC 13G/A | $29.99 $29.21 | ▼ −2.60% | ▼ −2.22% | $29.82 (−0.57%) |
Oct 26, 2026 6d ago | 8-K | $29.18 $29.99 | ▲ +2.78% | ▲ +2.22% | $29.82 (+2.19%) |
Aug 5, 2026 12w ago | 8-K | $20.00 $20.81 | ▲ +4.05% | ▲ +3.44% | $29.82 (+49.10%) |
Jun 17, 2026 19w ago | Insider Cluster | $12.64 $14.01 | ▲ +10.84% | ▲ +11.15% | $29.82 (+135.92%) |
Jun 15, 2026 19w ago | 144 | $12.21 $12.20 | ▼ −0.08% | ▲ +0.51% | $29.82 (+144.23%) |
Jun 15, 2026 19w ago | 144 | $12.21 $12.20 | ▼ −0.08% | ▲ +0.51% | $29.82 (+144.23%) |
May 6, 2026 25w ago | 8-K | $12.31 $12.31 | · 0.00% | ▲ +0.83% | $29.82 (−142.24%) |
May 5, 2026 25w ago | 8-K | $12.85 $13.01 | ▲ +1.25% | ▼ −0.14% | $29.82 (+132.06%) |
Apr 27, 2026 26w ago | 8-K | $12.15 $11.64 | ▼ −4.20% | ▼ −4.19% | $29.82 (+145.43%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers